This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
BCAR3 · Western blot design guide
BCAR3 Western Blot Planning Guide
Plan a BCAR3 Western blot around the catalog-observed 92.6 kDa band, image-backed PB9846 evidence, HPA controls, and verified protocol records.
Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
BCAR3 Western Blot Experimental Design Guide
Expected bands, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before running
| Expected band | 92.6 kDa | |
| Observed band | Not reported — verify product WB image | |
| Gel | 8-10% | |
| Positive control | Cerebral cortex | |
| Negative control | Oral mucosa |
Important caveats
Reasons your observed band may differ from the expected size.
| ⓘ | Calculated mass | 92.6 kDa |
| ⓘ | Localization | Cytoplasm / Cell junction, focal adhesion |
| ⓘ | Processing / PTM | Record-dependent |
| ⓘ | Reactivity | Human / Mouse / Rat |
Sample controls for BCAR3 Western blot
🧪Use Cerebral cortex as the first positive-control candidate and Oral mucosa as the HPA Not detected negative candidate.
Positive control: Cerebral cortex (High)
Negative control: Oral mucosa (Not detected)
HPA protein score determines control status; other expression data is supporting context only.
HPA tissue expression evidence for BCAR3
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart on each tissue page — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cerebral cortex | Reported tissue cells | High | Protein (HPA) | HPA → |
| Breast | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Adrenal gland | Reported tissue cells | Medium | Protein (HPA) | HPA → |
| Endometrium | Reported tissue cells | Medium | Protein (HPA) | HPA → |
Section 1
What Is the Expected BCAR3 Western Blot Band Size?
Use the product-observed 92.6 kDa band as the primary planning value and retain the UniProt calculated mass as context.
| 92.6 kDa | Matches the authoritative product WB observation. |
| 92.6 kDa calculated | Use as UniProt context, not as a replacement observed band. |
| Unexpected additional signal | Do not assign identity without orthogonal positive/negative controls. |
💡Expected BCAR3 appearancePlan around 92.6 kDa and keep the calculated mass as supporting context.
| Catalog-observed band | 92.6 kDa; use this as the primary experimental expectation. |
| Calculated mass | 92.6 kDa from UniProt O75815; retain as context. |
| Gel selection | 8-10%; shared with the recommended protocol and poster. |
| Specificity check | Compare the lead HPA positive and negative controls with PB9846. |
| Situation | Likely cause | Next action |
|---|---|---|
| 92.6 kDa | Matches the authoritative product WB observation. | Confirm with orthogonal controls and the linked product record. |
| Additional band | May reflect processing, modification, or non-specific signal. | Run a dilution series and compare positive/negative controls. |
| Weak signal | Target abundance or transfer may be limiting. | Verify transfer, increase positive-control abundance, and bracket exposure. |
Experiment evidence
Western blot images showing BCAR3 band
PB9846 · BCAR3Observed 92.6 kDa · product-specific WB image
← swipe / scroll for more images →
Real WB data behind the band-size expectations in this section.
Section 2
Real Curated BCAR3 Western Blot Protocols
Start with the molecular-weight rule, then compare verified publication-derived conditions.
| Sample / lysate | Cerebral cortex |
| Gel % | 8-10% |
| Load | 20-30 µg total protein per lane |
| Transfer | Semi-dry, standard transfer |
| Membrane | 0.45 µm PVDF |
| Blocking | 5% non-fat milk or 5% BSA in TBST |
| Primary | PB9846 at datasheet starting dilution |
| Primary incubation | Overnight at 4 °C with gentle agitation |
| Secondary | Species-matched HRP conjugate at validated dilution |
| Wash | 3 × 5 min in TBST |
| Detection | Chemiluminescent substrate |
| Exposure | Bracket exposures to avoid saturation |
Section 4
Advanced BCAR3 Western Blot Tips
Deeper troubleshooting and optimisation questions for BCAR3, answered from its protein features.
Which band should guide the blot?
Use 92.6 kDa, the observation attached to the authoritative PB9846 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 92.6 kDa expectation.
Which positive control should I start with?
Start with Cerebral cortex, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Oral mucosa as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 8-10% consistently across the quick facts, protocol table, and poster.
What transfer method to use for BCAR3 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9846 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
Compare only the supplied target-verified records: PMC10898485, PMC2740797, PMC4311507.
Boster reagents
BCAR3 Western Blot Reagents
Human/Mouse/Rat-reactive BCAR3 Western blot reagents with authoritative product imagery.
Real WB data
Anti-BCAR3 Antibody Picoband®
Cat # PB9846
Reactivity: Human, Mouse, Rat
Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.
Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.
References
- UniProt O75815
- Human Protein Atlas — BCAR3
- PB9846 product record
- PMC10898485 — Localized Administration of Bcar3 siRNA via Nano-Self-Assembly to Treat Idiopathic Pulmonary Fibrosis by Disrupting Macrophage-Fibroblast Crosstalk.
- PMC2740797 — AND-34/BCAR3 regulates adhesion-dependent p130Cas serine phosphorylation and breast cancer cell growth pattern.
- PMC4311507 — Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes.